Kymab Limited

Cecilia Deantonio

Stephen D Gillies

Ian Kirby

Jamie Iain Campbell

Miha Kosmac

Volker Germaschewski

Cassandra Van Krinks

Nikole Sandy

Thomas Gallagher

Stephen John Arkinstall

E-Chiang Lee

Matthew John McCourt

Richard Charles Alfred Sainson

Mohammed Hanif Ali

The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.

Anti-PD-L1 antibodies

Anti-PD-L1 and IL-2 cytokines

Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.

Anti-ICOS antibodies

Growing community of inventors

Cambridge, United Kingdom

Cecilia Deantonio